logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme class drugs

    FiltersReset Filters
    4 results

    • aldurazyme

      (laronidase)
      Genzyme Corporation
      Usage: ALDURAZYME® is indicated for treating adults and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), as well as those with moderate to severe symptoms of the Scheie form. Its safety for mildly affected Scheie patients and CNS effects are not established.

    • elaprase

      (idursulfase)
      Takeda Pharmaceuticals America, Inc.
      Usage: ELAPRASE is indicated for treating Hunter syndrome (MPS II) in patients 5 years and older, improving walking capacity. In patients aged 16 months to 5 years, it reduces spleen volume, but its effects on disease symptoms are unclear. Safety and efficacy for those under 16 months remain unestablished.

    • naglazyme

      (galsulfase)
      BioMarin Pharmaceutical Inc.
      Usage: NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) and has demonstrated effectiveness in improving walking and stair-climbing capacity.

    • vimizim

      (elosulfase alfa)
      BioMarin Pharmaceutical Inc.
      Usage: Vimizim (elosulfase alfa) is indicated for the treatment of Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.